Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Lin

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Critical Care Medicine|February 6, 2004
Genomic polymorphisms in sepsisMark T Lin, Timothy E Albertson
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature Medicine|December 5, 2022
Whole-body CD8<sup>+</sup> T cell visualization before and during cancer immunotherapy: a phase 1/2 trialLaura Kist de Ruijter, Pim P van de Donk, Jahlisa S Hooiveld-Noeken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Critical Care Medicine|February 6, 2004
Genomic polymorphisms in sepsisMark T Lin, Timothy E Albertson
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature Medicine|December 5, 2022
Whole-body CD8<sup>+</sup> T cell visualization before and during cancer immunotherapy: a phase 1/2 trialLaura Kist de Ruijter, Pim P van de Donk, Jahlisa S Hooiveld-Noeken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Pageof 1